Miraqules co-founder and CEO Sabir Hossain at all times knew he wished to observe in his father’s footsteps and run his personal enterprise. However he by no means thought he’d launch a biotech firm constructed round a know-how that will have been capable of assist his father after a near-tragic accident years earlier left him nearly bleeding to loss of life.
Bengaluru-based Miraqules developed a nanotechnology in powder kind that mimics blood clotting proteins. The blood clotting powder quickly produces fibrous compounds at room temperature which can be a excessive quantity to ratio and might take in blood shortly when utilized.
“This can be a product that will provide you with suggestions immediately,” Hossain advised TechCrunch. “If there’s a particular person bleeding, you apply it, and the bleeding stops. This entire factor occurs inside one or two minutes.”
Miraqules is a High 20 Startup Battlefield finalist and can be presenting this know-how on stage at TechCrunch Disrupt 2025, this week in San Francisco.
Hossain stated he developed the know-how nearly by chance.
He went to grad faculty for biomedical engineering and began working in a analysis lab centered on biomaterials the place his job was primarily to imitate the work of a doctorate pupil.
“I used to be actually unhealthy at that, truly,” Hossain stated. “Her job was to create 3D constructions that may assist in bone tissue progress, that would assist in bone technology. Each time I used to be synthesizing that materials, it was getting dismantled.”
Techcrunch occasion
San Francisco
|
October 27-29, 2025
In the future he took the dismantled particles and floor it right into a powder. He introduced this powder to a bunch engaged on blood clotting that was struggling to combine their resolution correctly to see if it might assist — and it labored.
“It clotted the entire blood inside possibly 5 to 10 seconds. I rushed to my professor after which from there we began to consider what made it occur,” Hossain stated. “We got here up with the utterly new course of of mixing off-the-shelf supplies right into a nanomaterial that mimics blood clotting proteins.”
Hossain then paired up along with his childhood buddy, Mubeen Midda, and so they began making an attempt to develop the know-how so it could possibly be taken out of the lab — with as little funding as attainable.
Since then, the corporate has been capable of safe 11 patents throughout seven totally different nations, together with India, america, and Israel.
Miraqules’ tech is already being piloted in a trauma care middle in India, and the corporate expects to get its regulatory clearance in India throughout the subsequent few months. It is also on monitor to obtain clearance from the U.S. Meals and Drug Administration in 2026.
“One factor we did from the start, we instantly went to the U.S. FDA, there’s something known as pre-submission. We tried to get their suggestions on what different vital issues that we have to do to get this product authorised, that helped us quite a bit.”
The corporate has reached these milestones with lower than $700,000 in capital raised, largely from grants.
Miraqules is trying to ramp up deployment and pilot packages heading into subsequent 12 months. It has already acquired potential curiosity from 10 totally different hospital chains in India and the Israeli Protection Forces.
If you wish to study from Miraqules firsthand, and see dozens of extra pitches, attend invaluable workshops, and make the connections that drive enterprise outcomes, head right here to study extra about this 12 months’s Disrupt, held October 27 to 29 in San Francisco.
{content material}
Supply: {feed_title}